| HOME >> MEDICINE >> TECHNOLOGY |
• Worldwide sales force size.
SECTION X: COLLABORATIVE ARRANGEMENTS
• Major joint venture, distribution, OEM, and licensing partners, both
industrial and academic.
• Terms of collaborative agreements and specific products involved.
SECTION XI: STRATEGIC DIRECTION
• Major strengths and weaknesses.
• Business, new product development, and marketing objectives
and strategies.
• Anticipated acquisitions, joint ventures, and divestitures.
LIST OF TABLESTable MO-1: World Pharmaceutical Market
by Major Product Segment
Table MO-2: World Ethical Pharmaceutical Market
by Geographic Region/Country
Table MO-3: World Ethical Pharmaceutical Market
by Major Drug Category
Table AZ-1: AstraZeneca Sales and Operating Profit Growth
Table AZ-2: AstraZeneca Sales by Therapeutic Category/Business
Table AZ-3: AstraZeneca Sales Growth by Therapeutic
Category/Business
Table AZ-4: AstraZeneca Sales by Major Drug/Business
Table AZ-5: AstraZeneca Sales Growth by Major Drug/Business
Table AZ-6: AstraZeneca Sales by Major Drug/Business and
Geographic Region
Table AZ-7: AstraZeneca Sales by Geographic Region and
Country
Table AZ-8: AstraZeneca Sales Growth by Geographic Region and
Country
Table BM-1: Bristol-Myers Squibb Sales and Operating Profit
Growth
Table BM-2: Bristol-Myers Squibb Sales by Major Division
Table BM-3: Bristol-Myers Squibb Sales by Major Division and
Geographic Region
Table BM-4: Bristol-Myers Squibb Sales Growth by Major Division
Table BM-5: Bristol-Myers Squibb Sales by Therapeutic Category
Table BM-6: Bristol-Myers Squibb Sales by Therapeutic Category
and Geographic Region
Table BM-7: Bristol-Myers Squibb Sales Growth by Therapeutic
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |